BofA Raises PT on Jazz Pharmaceuticals (JAZZ) to $225 From $217

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the most promising future stocks according to Wall Street analysts. On August 14, BofA raised the firm’s price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $225 from $217, keeping a Buy rating on the shares.

The firm told investors in a research note that it spoke with two key opinion leaders after the recent approval of Modeyso to treat an ultra-rare brain tumor. The leaders offered “positive feedback” on Modeyso uptake along with the odds of success for the confirmatory Phase 3 study.

The firm added that while the lead US indication for Modeyso for the recurrent setting is likely to be niche, the call from the experts left it “more assured” about the potential of the confirmatory ACTION trial, which may bolster peak US sales to greater than $400 million.

Jazz Pharmaceuticals (NASDAQ:JAZZ) develops medicines for serious diseases. Its primary marketed products include Xywav, Xyrem oral solution, Epidiolex oral solution, Rylaze, Zepzelca, Defitelio, and Vyxeos liposome for injection.

These medicines treat excess daytime sleepiness (EDS) in narcolepsy patients seven years of age or older, tepatic veno-occlusive disease (VOD), and other ailments.

While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.